Tag Archives: cognitive

#437598 Video Friday: Sarcos Is Developing a New ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

IROS 2020 – October 25-29, 2020 – [Online]
ROS World 2020 – November 12, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

NASA’s Origins, Spectral Interpretation, Resource Identification, Security, Regolith Explorer (OSIRIS-REx) spacecraft unfurled its robotic arm Oct. 20, 2020, and in a first for the agency, briefly touched an asteroid to collect dust and pebbles from the surface for delivery to Earth in 2023.

[ NASA ]

New from David Zarrouk’s lab at BGU is AmphiSTAR, which Zarrouk describes as “a kind of a ground-water drone inspired by the cockroaches (sprawling) and by the Basilisk lizard (running over water). The robot hovers due to the collision of its propellers with the water (hydrodynamics not aerodynamics). The robot can crawl and swim at high and low speeds and smoothly transition between the two. It can reach 3.5 m/s on ground and 1.5m/s in water.”

AmphiSTAR will be presented at IROS, starting next week!

[ BGU ]

This is unfortunately not a great video of a video that was taken at a SoftBank Hawks baseball game in Japan last week, but it’s showing an Atlas robot doing an honestly kind of impressive dance routine to support the team.

ロボット応援団に人型ロボット『ATLAS』がアメリカからリモートで緊急参戦!!!
ホークスビジョンの映像をお楽しみ下さい♪#sbhawks #Pepper #spot pic.twitter.com/6aTYn8GGli
— 福岡ソフトバンクホークス(公式) (@HAWKS_official)
October 16, 2020

Editor’s Note: The tweet embed above is not working for some reason—see the video here.

[ SoftBank Hawks ]

Thanks Thomas!

Sarcos is working on a new robot, which looks to be the torso of their powered exoskeleton with the human relocated somewhere else.

[ Sarcos ]

The biggest holiday of the year, International Sloth Day, was on Tuesday! To celebrate, here’s Slothbot!

[ NSF ]

This is one of those simple-seeming tasks that are really difficult for robots.

I love self-resetting training environments.

[ MIT CSAIL ]

The Chiel lab collaborates with engineers at the Center for Biologically Inspired Robotics Research at Case Western Reserve University to design novel worm-like robots that have potential applications in search-and-rescue missions, endoscopic medicine, or other scenarios requiring navigation through narrow spaces.

[ Case Western ]

ANYbotics partnered with Losinger Marazzi to explore ANYmal’s potential of patrolling construction sites to identify and report safety issues. With such a complex environment, only a robot designed to navigate difficult terrain is able to bring digitalization to such a physically demanding industry.

[ ANYbotics ]

Happy 2018 Halloween from Clearpath Robotics!

[ Clearpath ]

Overcoming illumination variance is a critical factor in vision-based navigation. Existing methods tackled this radical illumination variance issue by proposing camera control or high dynamic range (HDR) image fusion. Despite these efforts, we have found that the vision-based approaches still suffer from overcoming darkness. This paper presents real-time image synthesizing from carefully controlled seed low dynamic range (LDR) image, to enable visual simultaneous localization and mapping (SLAM) in an extremely dark environment (less than 10 lux).

[ KAIST ]

What can MoveIt do? Who knows! Let's find out!

[ MoveIt ]

Thanks Dave!

Here we pick a cube from a starting point, manipulate it within the hand, and then put it back. To explore the capabilities of the hand, no sensors were used in this demonstration. The RBO Hand 3 uses soft pneumatic actuators made of silicone. The softness imparts considerable robustness against variations in object pose and size. This lets us design manipulation funnels that work reliably without needing sensor feedback. We take advantage of this reliability to chain these funnels into more complex multi-step manipulation plans.

[ TU Berlin ]

If this was a real solar array, King Louie would have totally cleaned it. Mostly.

[ BYU ]

Autonomous exploration is a fundamental problem for various applications of unmanned aerial vehicles(UAVs). Existing methods, however, were demonstrated to have low efficiency, due to the lack of optimality consideration, conservative motion plans and low decision frequencies. In this paper, we propose FUEL, a hierarchical framework that can support Fast UAV ExpLoration in complex unknown environments.

[ HKUST ]

Countless precise repetitions? This is the perfect task for a robot, thought researchers at the University of Liverpool in the Department of Chemistry, and without further ado they developed an automation solution that can carry out and monitor research tasks, making autonomous decisions about what to do next.

[ Kuka ]

This video shows a demonstration of central results of the SecondHands project. In the context of maintenance and repair tasks, in warehouse environments, the collaborative humanoid robot ARMAR-6 demonstrates a number of cognitive and sensorimotor abilities such as 1) recognition of the need of help based on speech, force, haptics and visual scene and action interpretation, 2) collaborative bimanual manipulation of large objects, 3) compliant mobile manipulation, 4) grasping known and unknown objects and tools, 5) human-robot interaction (object and tool handover) 6) natural dialog and 7) force predictive control.

[ SecondHands ]

In celebration of Ada Lovelace Day, Silicon Valley Robotics hosted a panel of Women in Robotics.

[ Robohub ]

As part of the upcoming virtual IROS conference, HEBI robotics is putting together a tutorial on robotics actuation. While I’m sure HEBI would like you to take a long look at their own actuators, we’ve been assured that no matter what kind of actuators you use, this tutorial will still be informative and useful.

[ YouTube ] via [ HEBI Robotics ]

Thanks Dave!

This week’s UMD Lockheed Martin Robotics Seminar comes from Julie Shah at MIT, on “Enhancing Human Capability with Intelligent Machine Teammates.”

Every team has top performers- people who excel at working in a team to find the right solutions in complex, difficult situations. These top performers include nurses who run hospital floors, emergency response teams, air traffic controllers, and factory line supervisors. While they may outperform the most sophisticated optimization and scheduling algorithms, they cannot often tell us how they do it. Similarly, even when a machine can do the job better than most of us, it can’t explain how. In this talk I share recent work investigating effective ways to blend the unique decision-making strengths of humans and machines. I discuss the development of computational models that enable machines to efficiently infer the mental state of human teammates and thereby collaborate with people in richer, more flexible ways.

[ UMD ]

Matthew Piccoli gives a talk to the UPenn GRASP Lab on “Trading Complexities: Smart Motors and Dumb Vehicles.”

We will discuss my research journey through Penn making the world's smallest, simplest flying vehicles, and in parallel making the most complex brushless motors. What do they have in common? We'll touch on why the quadrotor went from an obscure type of helicopter to the current ubiquitous drone. Finally, we'll get into my life after Penn and what tools I'm creating to further drone and robot designs of the future.

[ UPenn ] Continue reading

Posted in Human Robots

#437471 How Giving Robots a Hybrid, Human-Like ...

Squeezing a lot of computing power into robots without using up too much space or energy is a constant battle for their designers. But a new approach that mimics the structure of the human brain could provide a workaround.

The capabilities of most of today’s mobile robots are fairly rudimentary, but giving them the smarts to do their jobs is still a serious challenge. Controlling a body in a dynamic environment takes a surprising amount of processing power, which requires both real estate for chips and considerable amounts of energy to power them.

As robots get more complex and capable, those demands are only going to increase. Today’s most powerful AI systems run in massive data centers across far more chips than can realistically fit inside a machine on the move. And the slow death of Moore’s Law suggests we can’t rely on conventional processors getting significantly more efficient or compact anytime soon.

That prompted a team from the University of Southern California to resurrect an idea from more than 40 years ago: mimicking the human brain’s division of labor between two complimentary structures. While the cerebrum is responsible for higher cognitive functions like vision, hearing, and thinking, the cerebellum integrates sensory data and governs movement, balance, and posture.

When the idea was first proposed the technology didn’t exist to make it a reality, but in a paper recently published in Science Robotics, the researchers describe a hybrid system that combines analog circuits that control motion and digital circuits that govern perception and decision-making in an inverted pendulum robot.

“Through this cooperation of the cerebrum and the cerebellum, the robot can conduct multiple tasks simultaneously with a much shorter latency and lower power consumption,” write the researchers.

The type of robot the researchers were experimenting with looks essentially like a pole balancing on a pair of wheels. They have a broad range of applications, from hoverboards to warehouse logistics—Boston Dynamics’ recently-unveiled Handle robot operates on the same principles. Keeping them stable is notoriously tough, but the new approach managed to significantly improve all digital control approaches by radically improving the speed and efficiency of computations.

Key to bringing the idea alive was the recent emergence of memristors—electrical components whose resistance relies on previous input, which allows them to combine computing and memory in one place in a way similar to how biological neurons operate.

The researchers used memristors to build an analog circuit that runs an algorithm responsible for integrating data from the robot’s accelerometer and gyroscope, which is crucial for detecting the angle and velocity of its body, and another that controls its motion. One key advantage of this setup is that the signals from the sensors are analog, so it does away with the need for extra circuitry to convert them into digital signals, saving both space and power.

More importantly, though, the analog system is an order of magnitude faster and more energy-efficient than a standard all-digital system, the authors report. This not only lets them slash the power requirements, but also lets them cut the processing loop from 3,000 microseconds to just 6. That significantly improves the robot’s stability, with it taking just one second to settle into a steady state compared to more than three seconds using the digital-only platform.

At the minute this is just a proof of concept. The robot the researchers have built is small and rudimentary, and the algorithms being run on the analog circuit are fairly basic. But the principle is a promising one, and there is currently a huge amount of R&D going into neuromorphic and memristor-based analog computing hardware.

As often turns out to be the case, it seems like we can’t go too far wrong by mimicking the best model of computation we have found so far: our own brains.

Image Credit: Photos Hobby / Unsplash Continue reading

Posted in Human Robots

#437261 How AI Will Make Drug Discovery ...

If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?

Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.

But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.

Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.

GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.

But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.

He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.

Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”

The results have turned what was once a decade-long war into a month-long skirmish.

In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.

Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.

They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.

Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.

Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.

But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.

Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.

On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.

Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.

One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.

Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.

Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.

Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.

Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”

How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: andreas160578 from Pixabay Continue reading

Posted in Human Robots

#437239 Using a quantum-like model to enable ...

Over the past few years, researchers have been trying to apply quantum physics theory to a variety of fields, including robotics, biology and cognitive science. Computational techniques that draw inspiration from quantum systems, also known as quantum-like (QL) models, could potentially achieve better performance and more sophisticated capabilities than more conventional approaches. Continue reading

Posted in Human Robots

#437209 A Renaissance of Genomics and Drugs Is ...

The causes of aging are extremely complex and unclear. But with longevity clinical trials increasing, more answers—and questions—are emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this article, I’ll explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

Genome Sequencing and Editing
Your genome is the software that runs your body. A sequence of 3.2 billion letters makes you “you.” These base pairs of A’s, T’s, C’s, and G’s determine your hair color, your height, your personality, your propensity for disease, your lifespan, and so on.

Until recently, it’s been very difficult to rapidly and cheaply “read” these letters—and even more difficult to understand what they mean. Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moore’s Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $1,500 in 2015.

Today, the cost of genome sequencing has dropped below $600, and according to Illumina, the world’s leading sequencing company, the process will soon cost about $100 and take about an hour to complete.

This represents one of the most powerful and transformative technology revolutions in healthcare. When we understand your genome, we’ll be able to understand how to optimize “you.”

We’ll know the perfect foods, the perfect drugs, the perfect exercise regimen, and the perfect supplements, just for you.
We’ll understand what microbiome types, or gut flora, are ideal for you (more on this in a later article).
We’ll accurately predict how specific sedatives and medicines will impact you.
We’ll learn which diseases and illnesses you’re most likely to develop and, more importantly, how to best prevent them from developing in the first place (rather than trying to cure them after the fact).

CRISPR Gene Editing
In addition to reading the human genome, scientists can now edit a genome using a naturally occurring biological system discovered in 1987 called CRISPR/Cas9.

Short for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, the editing system was adapted from a naturally-occurring defense system found in bacteria.

Here’s how it works. The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to “remember” the viruses (or closely related ones), and defend against future invasions. If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses’ DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus.

Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods. As a result, CRISPR/Cas9 has swept through labs around the world as the way to edit a genome. A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.

2018: Filled With CRISPR Breakthroughs
Early results are impressive. Researchers have used CRISPR to genetically engineer cocaine resistance into mice, reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs, and reduce genetic deafness in mice.

Already this year, CRISPR-edited immune cells have been shown to successfully kill cancer cells in human patients. Researchers have discovered ways to activate CRISPR with light and use the gene-editing technology to better understand Alzheimer’s disease progression.

With great power comes great responsibility, and the opportunity for moral and ethical dilemmas. In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera. Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.

To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells. Because Jiankui forged ethical review documents and misled doctors in the process, he was sentenced to three years in prison and fined $429,000 last December.

Coupled with significant ethical conversations necessary for progress, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.

Senolytics, Nutraceuticals, and Pharmaceuticals
Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.

What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely. These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse. Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification to localized inflammatory conditions such as osteoarthritis to diminished lung function.

Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.

Prominent companies in the field include the following:

Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology, and pulmonary disease.

Oisin Biotechnologies is pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.

SIWA Therapeutics is working on an immunotherapy approach to the problem of senescent cells.

In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.

(1) Rapamycin

Originally extracted from bacteria found on Easter Island, rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division. Currently, rapamycin derivatives are widely used for immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan and enhanced cognitive and immune function.

PureTech Health subsidiary resTORbio (which went public in 2018) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.

Results of the drug’s recent clinical trial include decreased incidence of infection, improved influenza vaccination response, and a 30.6 percent decrease in respiratory tract infection.

Impressive, to say the least.

(2) Metformin

Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients. Researchers have found that metformin also reduces oxidative stress and inflammation, which otherwise increase as we age. There is strong evidence that metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.

Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of metformin’s protective effect against cancer.

(3) Nutraceuticals and NAD+

Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels.

NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. It’s been shown that NAD+ levels decline as we age.

The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend one’s lifespan. Elysium’s first clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.

Conclusion
These are just a taste of the tremendous momentum that longevity and aging technology has right now. As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.

The next article in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging, and vitality.

We are edging closer toward a dramatically extended healthspan—where 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: Arek Socha from Pixabay Continue reading

Posted in Human Robots